Purpurowicz Piotr, Kaminski Tomasz W, Kordan Władysław, Korzekwa Anna J, Purpurowicz Zbigniew, Jabłonowski Zbigniew
Department of Urology and Urological Oncology, Municipal Hospital in Olsztyn, 10-045 Olsztyn, Poland.
Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Biomedicines. 2024 Jun 27;12(7):1426. doi: 10.3390/biomedicines12071426.
The incidence of bladder cancer worldwide in the last three decades has been increasing in both men and women. So far, there is no established non-invasive bladder cancer biomarker in daily clinical practice. Semaphorin 6D (sema6D) is a transmembrane protein that belongs to the class VI semaphorins. The aim of this study was to evaluate for the first time the potential role of sema6D in bladder cancer. The study group consisted of 40 patients with non-muscle-invasive bladder cancer (NMIBC) and the control group of 20 patients without malignancies. There was a statistically significantly higher urinary sema6D concentration in patients than controls ( < 0.05) but no significant difference in plasma 6D. There were no statistically significant differences in urinary or plasma concentration of sema6D between low- or high-grade cancer and according to the tumor stage in TNM classification. There was a statistically significant negative correlation between plasma sema6D and age of patients (R = -0.6; = 0.019). Plasma sema6D does not seem to be useful in the clinical practice at this point. However, the urinary sema6D concentration could potentially serve as a marker of NMIBC used for diagnostic purposes, monitoring, and early relapse detection or the assessment of the treatment efficacy. Urinary sema6D is probably not associated with the grading or staging of NMIBC, so it cannot be used for the prediction of disease prognosis.
在过去三十年中，全球范围内膀胱癌的发病率在男性和女性中均呈上升趋势。到目前为止，在日常临床实践中尚无已确立的非侵入性膀胱癌生物标志物。信号素6D（sema6D）是一种跨膜蛋白，属于VI类信号素。本研究的目的是首次评估sema6D在膀胱癌中的潜在作用。研究组由40例非肌层浸润性膀胱癌（NMIBC）患者组成，对照组由20例无恶性肿瘤的患者组成。患者的尿sema6D浓度在统计学上显著高于对照组（<0.05），但血浆sema6D浓度无显著差异。低级别或高级别癌症之间以及根据TNM分类的肿瘤分期，尿或血浆中sema6D的浓度在统计学上无显著差异。血浆sema6D与患者年龄之间存在统计学上显著的负相关（R = -0.6； = 0.019）。目前血浆sema6D在临床实践中似乎并无用处。然而，尿sema6D浓度有可能作为NMIBC的标志物，用于诊断、监测、早期复发检测或治疗效果评估。尿sema6D可能与NMIBC的分级或分期无关，因此不能用于疾病预后的预测。
